ProfileGDS5678 / 1440913_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 9% 9% 9% 10% 10% 12% 9% 9% 9% 9% 9% 9% 9% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.233919
GSM967853U87-EV human glioblastoma xenograft - Control 22.21819
GSM967854U87-EV human glioblastoma xenograft - Control 32.214499
GSM967855U87-EV human glioblastoma xenograft - Control 42.1940410
GSM967856U87-EV human glioblastoma xenograft - Control 52.1971410
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.3439112
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.230629
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.195119
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.187999
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.20589
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.202199
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.204869
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.21069
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.206979